These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26679066)

  • 1. Strontium Ranelate Reduces the Fracture Incidence in a Growing Mouse Model of Osteogenesis Imperfecta.
    Shi C; Hu B; Guo L; Cao P; Tian Y; Ma J; Chen Y; Wu H; Hu J; Deng L; Zhang Y; Yuan W
    J Bone Miner Res; 2016 May; 31(5):1003-14. PubMed ID: 26679066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are Changes in Composition in Response to Treatment of a Mouse Model of Osteogenesis Imperfecta Sex-dependent?
    Boskey AL; Marino J; Spevak L; Pleshko N; Doty S; Carter EM; Raggio CL
    Clin Orthop Relat Res; 2015 Aug; 473(8):2587-98. PubMed ID: 25903941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparable Effects of Strontium Ranelate and Alendronate Treatment on Fracture Reduction in a Mouse Model of Osteogenesis Imperfecta.
    Shi C; Sun B; Ma C; Wu H; Chen R; He H; Zhang Y
    Biomed Res Int; 2021; 2021():4243105. PubMed ID: 33506016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raloxifene reduces skeletal fractures in an animal model of osteogenesis imperfecta.
    Berman AG; Wallace JM; Bart ZR; Allen MR
    Matrix Biol; 2016; 52-54():19-28. PubMed ID: 26707242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sclerostin-Antibody Treatment Decreases Fracture Rates in Axial Skeleton and Improves the Skeletal Phenotype in Growing oim/oim Mice.
    Cardinal M; Dessain A; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
    Calcif Tissue Int; 2020 May; 106(5):494-508. PubMed ID: 32025752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysfunction of Caveolae-Mediated Endocytic TβRI Degradation Results in Hypersensitivity of TGF-β/Smad Signaling in Osteogenesis Imperfecta.
    Shi C; Sun B; Wu H; Zhang R; Wu L; Guo L; Li C; Xi Y; Yuan W; Zhang Y; Xu G
    J Bone Miner Res; 2023 Jan; 38(1):103-118. PubMed ID: 36321807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta.
    Cardinal M; Tys J; Roels T; Lafont S; Ominsky MS; Devogelaer JP; Chappard D; Mabilleau G; Ammann P; Nyssen-Behets C; Manicourt DH
    Bone; 2019 Jul; 124():137-147. PubMed ID: 31051315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
    Sinder BP; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Bone; 2015 Feb; 71():115-23. PubMed ID: 25445450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse.
    Misof BM; Roschger P; Baldini T; Raggio CL; Zraick V; Root L; Boskey AL; Klaushofer K; Fratzl P; Camacho NP
    Bone; 2005 Jan; 36(1):150-8. PubMed ID: 15664013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model.
    McCarthy EA; Raggio CL; Hossack MD; Miller EA; Jain S; Boskey AL; Camacho NP
    Pediatr Res; 2002 Nov; 52(5):660-70. PubMed ID: 12409511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta.
    Camacho NP; Raggio CL; Doty SB; Root L; Zraick V; Ilg WA; Toledano TR; Boskey AL
    Calcif Tissue Int; 2001 Aug; 69(2):94-101. PubMed ID: 11683430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta.
    Bargman R; Huang A; Boskey AL; Raggio C; Pleshko N
    Connect Tissue Res; 2010 Apr; 51(2):123-31. PubMed ID: 20053133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrafibrillar mineralization deficiency and osteogenesis imperfecta mouse bone fragility.
    Maghsoudi-Ganjeh M; Samuel J; Ahsan AS; Wang X; Zeng X
    J Mech Behav Biomed Mater; 2021 May; 117():104377. PubMed ID: 33636677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength.
    Sinder BP; White LE; Salemi JD; Ominsky MS; Caird MS; Marini JC; Kozloff KM
    Osteoporos Int; 2014 Aug; 25(8):2097-107. PubMed ID: 24803333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.
    Bargman R; Posham R; Boskey AL; DiCarlo E; Raggio C; Pleshko N
    Osteoporos Int; 2012 Mar; 23(3):1141-50. PubMed ID: 21901481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta.
    Delos D; Yang X; Ricciardi BF; Myers ER; Bostrom MP; Camacho NP
    J Orthop Res; 2008 Feb; 26(2):153-64. PubMed ID: 17729310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic impact of low amplitude high frequency whole body vibrations on the osteogenesis imperfecta mouse bone.
    Vanleene M; Shefelbine SJ
    Bone; 2013 Apr; 53(2):507-14. PubMed ID: 23352925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irisin reduces bone fracture by facilitating osteogenesis and antagonizing TGF-β/Smad signaling in a growing mouse model of osteogenesis imperfecta.
    Sun B; Wu H; Lu J; Zhang R; Shen X; Gu Y; Shi C; Zhang Y; Yuan W
    J Orthop Translat; 2023 Jan; 38():175-189. PubMed ID: 36439629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlations Between Bone Mechanical Properties and Bone Composition Parameters in Mouse Models of Dominant and Recessive Osteogenesis Imperfecta and the Response to Anti-TGF-β Treatment.
    Bi X; Grafe I; Ding H; Flores R; Munivez E; Jiang MM; Dawson B; Lee B; Ambrose CG
    J Bone Miner Res; 2017 Feb; 32(2):347-359. PubMed ID: 27649409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone injections improve bone quality in a mouse model of osteogenesis imperfecta.
    King D; Jarjoura D; McEwen HA; Askew MJ
    J Bone Miner Res; 2005 Jun; 20(6):987-93. PubMed ID: 15883639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.